Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness

On June 9, 2023, the Food and Drug Administration’s (FDA) advisory committee unanimously voted to approve lecanemab, moving the treatment one step closer to full FDA approval. In the lead up to the FDA’s official announcement expected in early July, Dr. Paul Aisen joins the podcast to discuss Alzheimer’s disease clinical trials. Aisen,  the founding director of the Alzheimer’s Therapeutic Research Institute (ATRI) and a leading figure in Alzheimer’s disease research for over three decades, talks about the Phase 3 clinical trials for lecanemab and gantenerumab and shares highlights from the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference. Guest: Paul Aisen, MD, professor of neurology, Keck School of Medicine, University of Southern California, Director, Alzheimer’s Therapeutic Research Institute  Show Notes Find out more about Dr. Aisen on Keck School of Medicine’s website. Follow the Alzheimer’s Therapeutic Research Institute on Facebook andTwitter. Listen to the episode with Dr. Roderick Corriveau, “Mixed Dementia, Explained” on our website, Spotify, Apple Podcasts, Podbean, and all major podcast platforms. Connect with us Find transcripts and more at our website. Email Dementia Matters: [email protected] Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

There are no comments yet.

Please log in to write the first comment.